BioCryst Pharmaceuticals, Inc.
(NASDAQ:BCRX) today announced that the
National Institute of Allergy and Infectious Diseases (NIAID)
has contracted with BioCryst for the development of
as a treatment for Marburg virus disease. NIAID, part of the National Institutes of Health, has made an initial award of $5.0 million to BioCryst. The total funding could be up to $22.0 million over five years, if all contract options are exercised. BCX4430 is the lead compound in BioCryst’s broad-spectrum antiviral (BSAV) research program.
The goals of this contract are to file investigational new drug (IND) applications for intravenous (i.v.) and intramuscular (i.m.) BCX4430 for the treatment of Marburg virus disease, and to conduct an initial Phase 1 human clinical trial. The contract supports the appropriate IND-enabling program and the initial clinical trial.
“Filovirus diseases such as Marburg virus hemorrhagic fever represent serious threats to national security, and the U.S. Government has prioritized the development of medical countermeasures against these diseases. We are very pleased that NIAID has selected BioCryst’s BCX4430 BSAV program as an early development project in this important field,” said
Dr. William P. Sheridan, Chief Medical Officer
This project will be funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201300017C.
About the BSAV Program & BCX4430
The objective of BioCryst’s BSAV research program is to develop broad-spectrum parenteral and oral therapeutics for viruses that pose a threat to health and national security. The lead BSAV compound is BCX4430, an RNA dependent-RNA polymerase inhibitor that has demonstrated broad-spectrum activity for multiple viruses and a favorable preliminary preclinical safety profile. BioCryst is developing BCX4430 in collaboration with U.S. Government Agencies following the Animal Rule regulatory pathway.